GRAIL, LLC (GRAL)vsNovartis AG ADR (NVS)
GRAL
GRAIL, LLC
$69.48
+9.59%
HEALTHCARE · Cap: $2.94B
NVS
Novartis AG ADR
$154.21
+1.37%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 36214% more annual revenue ($56.69B vs $156.12M). NVS leads profitability with a 22.5% profit margin vs -253.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
GRAL
Hold35
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GRAL.
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$154.21
$61.48 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 28.1% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -15.8% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 28.1% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
GRAL profiles as a growth stock while NVS is a value play — different risk/reward profiles.
GRAL carries more volatility with a beta of 3.22 — expect wider price swings.
GRAL is growing revenue faster at 28.1% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 35/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?